ClinicalTrials.gg
Active, not recruitingNCT06719141Updated Sep 15, 2026

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

A Phase 3 interventional study of LP352 and Placebo in Developmental and Epileptic Encephalopathy, sponsored by Longboard Pharmaceuticals. Active, not recruiting at 116 sites in 17 countries. Open to participants aged 2 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Longboard Pharmaceuticals (part of H. Lundbeck A/S) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
367
Allocation
Randomized
Ages
2 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 395 studies in Seizures with a site in United States — 75 open to participants now, 93 under way, 21 of them phase 3. Seizures · United States.

Enrollment
26th of 306
367 · median 56
Started
2024
with 19 others
Phase 3
84 of 395
15 open now
Primary completion
2026-10
later than 10 of 91 live
Registered
361st of 395
by date

Among the 395 studies in Seizures with a site in United States, this one is the 26th largest by enrollment of the 306 interventional ones that give a count, is one of 20 that started in 2024, is one of 84 in phase 3, reaches primary completion later than 10 of the 91 other live ones, and was the 361st registered.

Seizures

766 studies on the registry are indexed under Seizures; 134 are open to participants now.

Browse Seizures studies →

Open to participants now

75 of the 395 studies in Seizures with a site in United States are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.

This study: 2 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 395 studies in Seizures with a site in United States, or all of them as a file.
02

Study summary

This (DEEp OCEAN Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DEE. The study consists of 3 main phases: Screening, Titration period, Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 24 months.

03

Conditions studied

  • Developmental and Epileptic Encephalopathy

Keywords

  • Developmental and epileptic encephalopathy
  • LP352
  • Seizures
  • Bexicaserin
  • Antiseizure medications (ASMs)
  • Epilepsy
  • Lennox-Gastaut Syndrome (LGS)
  • Neurodevelopmental disorders
  • DEEp OCEAN
04

Who can participate

Ages eligible
2 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are characterized as having Lennox-Gastaut Syndrome (LGS) must fulfill all of the following criteria:

    • Onset of seizures at ≤8 years old
    • History of tonic/tonic-atonic seizures plus at least 1 of the following seizure type(s): atypical absence, atonic, myoclonic, focal impaired awareness, generalized tonic-clonic, nonconvulsive status epilepticus, or epileptic spasms
    • Presence of developmental plateauing or regression
    • History of electroencephalogram (EEG) showing generalized slow (\<2.5 Hertz [Hz]) spike-and-wave complexes
  • Participants who are characterized as having DEE (Other) must fulfill all of the following criteria:

    • Does not meet criteria for LGS
    • Onset of seizures at ≤5 years old
    • Presence of developmental plateauing or regression
    • History of multiple seizure types
    • History of interictal EEG background showing diffuse or multifocal slowing (with or without epileptiform activity)
  • The participant has a current occurrence of at least 1 of the following countable motor seizure types: generalized tonic-clonic, tonic (bilateral), clonic (bilateral), atonic (bilateral) with truncal/leg involvement, focal motor (including hemiclonic), and focal to bilateral tonic-clonic.
  • The participant has demonstrated an average of at least 4 countable motor seizures per month for each of the 3 months prior to Screening.
  • The participant has been taking 1 to 4 antiseizure medications (ASMs) at a stable dose for at least 4 weeks prior to Screening.
  • The participant, parent, or caregiver is willing and able (in the judgment of the investigator) to comply with completion of the diaries throughout the study.
  • The participant must be willing and able to provide written ; in instances where the participant is unable to provide consent, an appropriate legal representative.

Exclusion criteria

Exclusion Criteria:

  • The participant has a diagnosis of Dravet Syndrome (DS) or has a mutation of the Sodium channel protein type 1 subunit alpha (SCN1A) gene consistent with DS.
  • The participant has been admitted to a medical facility for treatment of status epilepticus requiring mechanical ventilation within 3 months prior to Screening.
  • The participant has a neurodegenerative disorder as indicated by magnetic resonance imaging or genetic testing.
  • The participant has an acquired lesion/injury unrelated to the primary etiology that could contribute as a secondary cause of seizures.
  • The participant is receiving exclusionary medications.
  • The participant is currently using any cannabis product or cannabidiol that is not in oral solution/capsule/tablet form, not obtained from a government-approved dispensary, or contains ≥50% Delta-9-tetrahydrocannabinol (THC).
  • The participant has unstable, neurologic (other than the disease being studied; eg, recurrent strokes), psychiatric, cardiovascular (eg, pulmonary arterial hypertension, cardiac valvulopathy, orthostatic hypotension/tachycardia), pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, hematopoietic, or endocrine disease or other abnormality which may impact the ability of the participant to participate or potentially confound the study results.
  • The participant is unable or unwilling to comply with any of the study requirements or timelines.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
367 participants (actual)

Study arms

  • Experimental
    LP352

    Participants will be titrated up to highest tolerated dose of LP352 during the Titration period (Visit 2 - Visit 5), followed by maintenance period (Visit 5 - Visit 8) and then taper/down titration period.

    Drug: LP352

  • Placebo comparator
    Placebo

    Placebo for LP352

    Drug: Placebo

Interventions

  • DrugLP352

    LP352 will be administered orally or through G-tube/ percutaneous endoscopic gastrostomy (PEG) tube

    Also known as: Bexicaserin

  • DrugPlacebo

    Participants will be administered with matching placebo orally or through G-tube/ PEG tube.

    Also known as: Placebo Comparator

06

What researchers measure

Primary outcomes

  1. Frequency Percent Change in Countable Motor Seizures During Treatment Compared to Baseline

    The percent change from Baseline in countable motor seizure frequency during Treatment will be calculated as countable motor seizure frequency during Treatment minus countable motor seizure frequency during Screening and divided by seizure frequency during Screening and multiplied by 100 where each seizure frequency will be based on number of seizures.

    Time frame: Baseline and up to 15 Weeks

Secondary outcomes

  1. Safety and Tolerability of LP352

    Safety and tolerability as measured by incidence and severity of Treatment Emergent Adverse Events (TEAEs), Serious Adverse events (SAEs), AEs leading to discontinuation and clinically significant changes in laboratory parameters (hematology, serum chemistry and Urinalysis), physical examination findings, vital signs, growth parameters (height and weight), 12-lead electrocardiograms (ECGs), Columbia-Suicide Severity Rating Scale (C-SSRS) responses, and Patient Health Questionnaire-9 (PHQ-9) total score and Question 9 score.

    Time frame: Up to 21 Weeks

  2. Percentage of participants with ≥ 50% Reduction in countable motor seizures during the Treatment compared to Baseline

    Time frame: Baseline and up to 15 Weeks

  3. Frequency Percent Change in Countable Motor Seizures during Maintenance compared to Baseline

    Time frame: Baseline and up to 15 Weeks

07

Study locations

116 sites

Showing the first 100 of 116 sites across 17 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Oct 2026, 23 months after the start.

Of 43 industry-sponsored phase 3 interventional studies under Seizures, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 79. This study's planned 23 months is below that.

Counting every sponsor, half of 51 studies reached it within 54 months; a quarter within 33 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2024
First posted
Dec 5, 2024
StartActual
Nov 11, 2024
Primary completionEst.
Oct 31, 2026
CompletionEst.
Nov 30, 2026
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06719141
Responsible party
Sponsor
First posted
Dec 5, 2024
Start date
Nov 11, 2024
Primary completion
Oct 31, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Sep 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bexicaserin

Start the discussion